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tiveness when correcting for the poorer-seeing eye.METHODS:An existing Markov
model comparing three treatment frequencies of Bevacizumab (Avastin) is used, to
investigate the effect of the correction of the poorer-seeing eye. We examined
several scenarios of the poorer-seeing eye; no influence(0%), 10% and 20% influence
of the utility of the better-seeing eye. In addition, it can be argued that treating the
poorer-seeing eye has a preventive function, as it can become the future better-
seeing eye. In the model a switch of the better-seeing eye is assumed after two and
four years. RESULTS: By including the correction of the utility of the poorer-seeing
eye the incremental cost-effectiveness ratio’s (ICER) change from €5,260, €31,167
and €3,712, to respectively €10,375, €60,124 and €7,377 (20% influence). Lowering the
influence from 20% to 0% has an effect of respectively, €13,706, €78,314 and €9,796.
When inserting a switch at two and four years, the ICER reduces from €10,375,
€60,124 and €7.377 to respectively €7,325, €53,649 and €4,848 at four years and
almost half at 2 years. CONCLUSIONS: The results show that overestimating the
QALY by excluding the poorer-seeing eye results in a lower incremental cost-effec-
tiveness. Poorer-seeing eyes should be used when modeling eye-diseases. Whether
the poorer-seeing eye contributes 20%, 10% or 0% has a small impact on the change
in ICER’s. The preventive function of treating the poorer-seeing eye should also be
taken into account.
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OBJECTIVES: To assess the economic burden of unresectable or metastatic (“ad-
vanced”) melanoma. METHODS: Using data from calendar years (CY) 2003-2008
from a large health insurance database and case-finding algorithms that we devel-
oped for use in such data, we identified all persons with Stage III unresectable or
Stage IV melanoma at initial presentation, as well as those who presented with
earlier-stage disease in prior years and progressed to advanced disease (i.e., recur-
rent cases). We tallied health care costs on an all-cause basis for all such persons
alive for one or more day in CY2008. Health care costs were tallied by category of
utilization (e.g., hospitalizations, outpatient visits, outpatient pharmacotherapy,
etc.) as well as on an overall basis. Reimbursed amounts were used as a proxy for
costs. RESULTS: We identified 1527 persons with advanced melanoma in CY2008
(Stage III unresectable, 267; Stage IV, 1260). Stage IV patients were more likely to be
hospitalized during the year than those with Stage III disease (39% vs 26%, respec-
tively; p0.01). Mean (SD) total annual cost per patient was $42,848 ($66,279), and
was higher for those with Stage IV versus Stage III unresectable disease ($45,786 vs
$28,983; p0.01). Outpatient services (including the cost of infused drugs) ac-
counted for approximately 54% of total costs, while hospitalization and outpatient
pharmacotherapy accounted for 37% and 9%, respectively. CONCLUSIONS: Our
findings suggest that the economic burden of advanced melanoma is high, espe-
cially in patients with Stage IV disease.
PSS29
TREATMENT PATTERNS OF PSORIASIS PATIENTS AND TRENDS OVER TIME
Zhang F1, Guerin A2, Gauthier G2, Day R1, Khan Z1
1Celgene Corporation, Summit, NJ, USA, 2Analysis Group, Ltee., Montreal, QC, Canada
OBJECTIVES: Several treatment options are available for psoriasis, an incurable
dermatological condition, but there is limited information on actual treatment
patterns. This retrospective study aimed to provide a snap shot of the use of pso-
riasis medications and recent trends over time in current clinical practice in pso-
riasis patients with co-morbid conditions. METHODS: Adult patients with 2 doc-
umented psoriasis diagnoses (ICD-9 codes: 696.1 were selected from a large US
administrative claims database (2004-2008). The index date was defined as the
latest date with a psoriasis diagnosis. Psoriasis treatments, including topical ther-
apies, phototherapy, conventional systemic therapies, and biologics, were identi-
fied during the 6 months following the index date and described for the entire
psoriasis population, a sub-group of obese patients (body mass index [BMI] 30),
and stratified by index year to examine trends over time. RESULTS: A total of
106,128 psoriasis patients were selected. The mean age was 5215 years and 52%
were female. Overall, 62.3% of psoriasis patients were on topical therapies, 12.1%
used biologics, 7.4% used other immunosuppressant agents, 5.6% used photother-
apy and 27.2% were untreated. Over time, biologic use increased from 8.7% in 2004
to 21.0% in 2008, while the use of other treatments did not show this trend. In the
sub-group of psoriasis patients with BMI information (N1874; 646 obese and 1,228
non-obese), more obese patients were treated with biologics (20.0% vs. 15.0%) and
other immunosuppressant agents (12.4% vs. 6.9%) than non-obese patients.
CONCLUSIONS: The majority of psoriasis patients were treated with topical ther-
apies. There has been an increase in the proportion of patients using biologics in
the recent years. In addition, biologics and other immunosuppressant therapies
were more likely to be used among obese patients.
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OBJECTIVES: Evidence is limited on the extent to which health state utility decre-
ments differ between changes in the better-seeing and worse-seeing eyes follow-
ing treatment. This study presents estimates of the utility levels as a function of the
visual acuity in the treated eye stratified by the condition of the fellow (untreated)
eye in patients treated for visual impairment caused by diabetic macular edema
(DME). METHODS: Data from RESTORE clinical trial with (12 months follow up of
ranibizumab treatment for DME) were analyzed. 8 health states were defined by
BCVA in the treated eye. Mean utility was estimated using multivariate regression
(repeated measures analysis). The regression was tested for confounders including
disease severity. The influence of BCVA in the fellow eye on the health index was
explored by separating treated eyes into cohorts according to visual acuity of the
fellow eye: better, equal or worse. Results were compared with other published
studies. RESULTS: The utility ranged from 0.86 (SE0.014) with BCVA 76-100 letters
(Snellen score) to 0.55 (SE0.083) with BCVA 0-25 letters (unadjusted model). Dis-
ease severity had a non-significant effect on this range (p0.05). BCVA of the worse
seeing eye had a significant impact on the utility (utility decrement -0.11 from
76-100 letters to 36-45 letters), with better seeing eyes demonstrating a utility dec-
rement -0.14 from 76-100 letters to 36-45 letters. Results were inconclusive for
health states below 35 letters due to small numbers. CONCLUSIONS: This explor-
ative analysis reveals that visual acuity of a worse seeing eye has a significant
impact on utility and may be comparable to the impact on the better seeing eye.
Importantly, these findings are supported by improvements in quality of life ob-
served using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-
25) for DME patients treated with ranibizumab in the worse seeing eye in RESTORE.
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OBJECTIVES: HRQoL is often impaired in patients with skin diseases but it is often
assessed with different instruments, generating data not directly comparable or
not suitable to estimate utility. Assessing the association between HRQoL mea-
sures obtained with different instruments could be useful to obtain more complete
data. The dermatology life quality index (DLQI) is a condition-specific question-
naire widely used to assess HRQoL in subjects with skin diseases. We aimed to
estimate the association between EQ-5D VAS and utility score with the DLQI sum-
mary score (max 30 and min 0; higher score corresponds to more impaired quality
of life) in patients with severe CHE and refractory to therapy with topical potent
corticosteroids.METHODS:Within a naturalistic, multicentre cost-of-illness study;
patients aged18 years, consecutively accessing at the participating centres, com-
pleted the EQ-5D and DLQI questionnaires during the enrolment visit. Individual
patient utility was estimated from EQ-5D responses using the standard UK scoring
algorithm. A multivariable linear regression model was built to estimate the asso-
ciation between the EQ-5D VAS and utility score with the DLQI summary score,
adjusted for age and gender. The bootstrap resampling was used to calculate stan-
dard errors and 95% confidence intervals. RESULTS: A total of 104 patients (mean
ageSD44.515.0, 39.4% male) were enrolled. DLQI meanSD summary score
was 11.36.3, EQ-5D VAS meanSD60.423.3 and EQ-5D utility
meanSD0.500.31. EQ-5D VAS and utility showed a linear negative relationship
with DLQI summary score. One point rise in DLQI was associated with a EQ-5D VAS
decrease of 1.84 (SE0.34; 95%CI-2.52,-1.16; R20.261) and a utility index decrease
of 0.025 (SE0.005; 95%CI-0.035,-0.014; R20.254) in utility. CONCLUSIONS: DLQI
summary score is significantly associated with the EQ-5D VAS and utility index.
Our results could be useful to derive EQ-5D information from DLQI data, to perform
economic evaluations targeted to patients with severe CHE refractory to therapy
with topical potent corticosteroids.
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OBJECTIVES: The aims of the study were to estimate score ranges associated with
dry eye severity based on the Impact of Dry Eye on Everyday Life (IDEEL) Symptom
Bother (SB) domain, and to evaluate the overall performance of the SB domain.
METHODS: A total of 210 participants (130 dry eye patients, 32 Sjogren’s patients
and 48 controls) completed the IDEEL SB domain and reported their degree of dry
eye severity on an ordinal response scale of none, mild, moderate or severe. Ordinal
regression analysis using a proportional-odds model was used to provide SB cut-off
score ranges associated with the highest probability of membership of each of the
four individual response categories. ROC analysis was used to examine the speci-
ficity and sensitivity of the overall SB scale. RESULTS: Ordinal regression revealed
SB to be a significant predictor of patient-reported dry eye severity (2225.59,
p0.001). Examination of individual probabilities associated with each SB score
revealed that the following score ranges were associated with the highest proba-
bility of membership of each dry eye category: None (0-16), Mild (17-38), Moderate
(39-65), Severe (66). ROC curve analysis revealed excellent performance of the SB
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